Skip to main content

Glaucus Proteomics To Rely On Dutch Supercomputing Brawn

NEW YORK, April 24-Glaucus Proteomics said today that it had struck agreements with SARA, the Dutch supercomputing center, and GigaPort, an Internet technology initiative funded by the Dutch government.


Glaucus intends to use the supercomputer center's muscle to characterize its collection of fully human antibodies, with the aim of developing antibody microarrays. The company also plans to identify biomarker patterns that can help fine-tune drug development.


Financial specifics were not disclosed.


Glaucus will have access to TERAS, a 1024 CPU system made up of two SGI Origin 3800 512 CPU systems with maximum 1 teraflop performance.


The company will connect to the facility via the GigaPort network, a broadband connection expected to provide10 gigabit/sec access.


Through this alliance, Glaucus will also have expert help with parallel code optimization, access to remote data backup, and remote help for in-house systems management.


Based in Utrecht, the Netherlands, Glaucus Proteomics is developing antibody and protein array technologies for drug development.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.